|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||31.26 - 34.20|
|52 Week Range||10.00 - 35.37|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.50|
Suppose you invest in all three of these healthcare companies, and two of them go belly up. Here are our selections for biotech stocks that can run up 1,000% by 2027. George Budwell (Intellia Therapeutics): If you're on the hunt for a stock that can produce life-changing gains over the next five years, the beaten-down biotech industry is definitely a good place to start your search.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 1, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock to three employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee o